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The 2014–15 Ebola virus (EBOV) outbreak, originally
reported during March 2014 in the Western African nation of
Guinea, has shown itself to be resistant to traditional con-
tainment methods, with over 28,000 infections and 11,000
deaths over 18 months. Recently, news that a Scottish nurse
had relapsed to EBOV disease with neurological symptoms
at 10 months after recovery have astonished experts. The
prolonged nature of the outbreak has led to questions
whether EBOV can become endemic in the human popula-
tion, an undesirable outcome due to the large amount of
resources required to keep this virus under control. In this
commentary, we discuss aspects EBOV disease with those
caused by pathogens considered endemic in humans, as
well as factors which may contribute to sustained EBOV
transmission in humans.
Ebola virus (EBOV), of the genus Ebolavirus and family
Filoviridae, was historically regarded as a re-emerging
pathogen, in which natural infections of humans are sporadic
and unpredictable, often with several years passing by
before the emergence of a new case. EBOV infection is
associated with high case fatality rates (CFR) in humans (up
to 90%), but past disease outbreaks due to EBOV lasted
only several months on average, and fatal cases numbered
at most in the hundreds (CDC.gov, 2014). As such, EBOV
was considered a minor public health threat in Africa at the
time. Perceptions of this virus changed when the largest
documented EBOV outbreak, ﬁrst reported during March
2014, ran rampant through the Western African nations of
Guinea, Sierra Leone and Liberia, causing over 28,000
infections and 11,000 deaths over the past 18 months
(WHO.int, 2015a).
Continued efforts by the local and international commu-
nities are having an observable effect in mostly conﬁning
EBOV transmission within the countries mentioned above,
and the numbers of new weekly cases have been declining
from a peak of over 700 in mid-September 2014 (WHO.int,
2015a). Since April 5th, 2015, the numbers of new cases
reported weekly have ﬂuctuated between 9 and 35, and this
number has been less than 10 since July 26th, 2015 (Fig. 1).
However, getting to zero cases overall has proven to be a
challenge and of the three most heavily affected countries,
only Liberia has been declared EBOV-free, on September
3rd, 2015 (WHO.int, 2015b). During this prolonged outbreak,
some experts have questioned whether EBOV can become
endemic within a human population (WHO Ebola Response
Team, 2014) (NPR.org, 2014), a situation characterized by
low levels of sustained virus transmission between humans,
and the potential for a new outbreak to occur if this trans-
mission is not successfully halted.
Can EBOV become endemic in the human population? If
we contemplate other pathogens that are considered endemic
within humans, such as Hepatitis B virus (HBV), Varicella
Zoster virus (VZV) and human immunodeﬁciency virus (HIV),
patients exposed to these viruses very rarely display major,
speciﬁc symptoms early in the course of infection. In many
cases the patients themselves do not know that they have
been infected, and thus unknowingly transmit the virus to other
susceptible hosts. In contrast, EBOV infection is typiﬁed by
general, ﬂu-like symptoms that rapidly progresses to severe
hemorrhagic fever and multiple-organ failure within between
7–14 days, accompanied by very visible signs of disease such
as rash (Feldmann et al., 2013). Patients are not known to be
contagious during the incubation period (WHO.int, 2014), and
the virus is primarily transmitted during advanced and terminal
EBOV disease (Dowell et al., 1999). While asymptomatic
infections with EBOV in humans have been documented on
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previous occasions (Baxter, 2000) (Becquart et al., 2010),
there is no evidence thus far that asymptomatic humans can
shed live virus. These factors prevent “silent” EBOV spread
within an unsuspecting population.
On the other hand, live virus has been found in the semen
of convalescent survivors at least 3 months after infection
(Rowe et al., 1999) (Rodriguez et al., 1999). A Liberian
female, who likely contracted EBOV after unprotected sex
with a man that had recently recovered from infection
(CDC.gov, 2015), showed that some EBOV survivors may
still be contagious after recovery from the disease. During
the 2014–15 outbreak, live EBOV has also been isolated
from the ocular ﬂuids of a physician who had survived
infection, 9 weeks after the clearance of viremia (Varkey
et al., 2015). The relapse of a Scottish nurse that had sur-
vived EBOV infection 10 months previously (Promedmail.
org, 2015) suggests that supplementary diagnostics tests, in
addition to viremia quantiﬁcation by reverse transcription-
quantitative polymerase chain reaction (RT-qPCR), may be
needed to conﬁrm the elimination of EBOV in convalescent
survivors. Heightened awareness regarding the possibility of
recovering survivors harbouring live EBOV is necessary, but
due to the lower amounts of virus present within convales-
cent patients compared to those with advanced EBOV dis-
ease, it is unlikely that survivors play a major role with
regards to EBOV propagation in humans.
From an evolutionary standpoint, EBOV does not have a
signiﬁcantly higher mutation rate (1.23 × 10−3 substitutions
per site per year (Tong et al., 2015)) compared to other RNA
viruses (Jenkins et al., 2002), and to date there are only ﬁve
known member species of Ebolavirus. Published studies
have also shown that EBOV is not signiﬁcantly evolving,
despite undergoing extensive passaging in humans during
the 2014–15 outbreaks (Hoenen et al., 2015) (Tong et al.,
2015). Therefore, the evidence at hand does not support the
virus becoming endemic amongst the human population,
and current response measures, which have steadily low-
ered the number of new weekly infections over time, should
be sufﬁcient in eventually ending the prolonged EBOV out-
break in Western Africa. However, the existence of possible
“super-spreaders” of disease (Wong et al., 2015), and the
relapse of Scottish nurse to EBOV disease is a reminder that
close surveillance for any potential reoccurrence of EBOV
disease in the human population is needed.
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Figure 1. Numbers of new EBOV infections per week in Guinea, Sierra Leone and Liberia. Numbers are reported by the World
Health Organization, and the dates are from March 15th to September 27th, 2015.
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studies with human or animal subjects performed by any of the
authors.
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